Search

Displaying results 6451 - 6460 of 7604 in total
  1. Drug

    ARX517

    go.drugbank.com/drugs/DB23076
    Investigational

    ARX517 is under investigation in clinical trial NCT04662580 (ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer).

  2. Drug

    Alanosine

    go.drugbank.com/drugs/DB05540
    Investigational

    An amino acid analogue and antibiotic derived from the bacterium Streptomyces alanosinicus with antimetabolite and potential antineoplastic activities.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    FF-10101-01

    go.drugbank.com/drugs/DB16050
    Investigational

    FF-10101-01 is under investigation in clinical trial NCT03194685 (Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia).

  4. Drug

    Darovasertib

    go.drugbank.com/drugs/DB16059
    Investigational

    IDE-196 is under investigation in clinical trial NCT03947385 (Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions).

  5. Drug

    Trastuzumab duocarmazine

    go.drugbank.com/drugs/DB16342
    Investigational

    Physician's Choice in Participants With Her2-positive Locally Advanced or Metastatic Breast Cancer).

  6. Drug

    Sabestomig

    go.drugbank.com/drugs/DB19326
    Investigational

    Sabestomig is under investigation in clinical trial NCT05216835 (Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma).

  7. Drug

    Gamma-Arsono-Beta, Gamma-Methyleneadenosine-5'-Diphosphate

    go.drugbank.com/drugs/DB02937
    Experimental

    Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position. [PubChem]

  8. Drug

    BW-A 58C

    go.drugbank.com/drugs/DB06740
    Experimental

    antimalarial drug which undergoes extensive alkyl hydroxylation to a single t-butylhydroxy metabolite in man in vivo and also in human liver microsomes, where this is catalysed primarily by a 54 kDa CYP2C9 form

  9. Drug

    MYR-101

    go.drugbank.com/drugs/DB17075
    Investigational

    [L43567] The FDA has granted MYR-101 Fast Track, Rare Pediatric Disease (RPD), and Orphan Drug designations for the treatment of patients with Canavan disease.[L43572]

  10. Drug

    Ciglitazone

    go.drugbank.com/drugs/DB09201
    Experimental

    Developed by Takeda Pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class.